AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37592166 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV
Number of subjects: 189
Study 37592166 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ventilation with low spontaneous effort
Number of subjects: 189
Study 37592217 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention targeting categorical perception, rapid automatized naming, and phonemic analysis
Number of subjects: 0
Study 37592217 — intervention group
Group type: COMPARATOR
Intervention: Standard speech therapy remediation
Number of subjects: 0
Study 37592243 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD) (< 20 E% carbohydrates, 50-60 E% fat)
Number of subjects: 71
Study 37592243 — intervention group
Group type: COMPARATOR
Intervention: Control diet (50-60 E% carbohydrates, 20-30 E% fat)
Number of subjects: 71
Study 37592263 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation technique errors 'Breathe in', 'Hold breath', 'Breathe out calmly after inhalation'
Number of subjects: 1434
Study 37592263 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation technique errors 'Preparation', 'Hold inhaler in correct position during inhalation', 'Breathe in'
Number of subjects: 1434
Study 37592263 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall inhalation technique errors
Number of subjects: 1434
Study 37592263 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific combinations of inhalation technique errors
Number of subjects: 1434
Study 37592263 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing inhalation technique error count
Number of subjects: 1434
Study 37592272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 1108
Study 37592272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1108
Study 37592288 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 15
Study 37592290 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Number of subjects: 60
Study 37592290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 37592299 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical hysterectomy (RH)
Number of subjects: 1104
Study 37592299 — intervention group
Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy (RH)
Number of subjects: 1104
Study 37592303 — intervention group
Group type: EXPERIMENTAL
Intervention: High CLDN6 mRNA expression
Number of subjects: 460
Study 37592303 — intervention group
Group type: EXPERIMENTAL
Intervention: CLDN6 protein expression
Number of subjects: 460
Study 37592303 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-naïve subgroups and cohorts receiving neoadjuvant therapy
Number of subjects: 460
Study 37592314 — intervention group
Group type: EXPERIMENTAL
Intervention: User-centred strategy (includes TB-education booklet, contact-identification algorithm, instructional sputum-collection video, community-health-rider service, collaborative improvement meetings, regular audit-and-feedback reports, digital group-chat application)
Number of subjects: 12
Study 37592314 — intervention group
Group type: COMPARATOR
Intervention: Standard strategy
Number of subjects: 12
Study 37592314 — intervention group
Group type: EXPERIMENTAL
Intervention: User-centred strategy
Number of subjects: 12
Study 37592320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological active placebo intervention
Number of subjects: 0
Study 37592320 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological active placebo intervention
Number of subjects: 0
Study 37592320 — intervention group
Group type: COMPARATOR
Intervention: Natural course control group
Number of subjects: 0
Study 37592358 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (twice daily for three days, at least 30 min per session)
Number of subjects: 94
Study 37592358 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 94
Study 37592358 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 94
Study 37592359 — intervention group
Group type: EXPERIMENTAL
Intervention: Connect To Care (C2C) intervention delivered by a Care Coach via telephone and/or video, focusing on strengths-based approach with four components: identifying patient strengths, collaborative decision-making, resolving barriers to care, and monitoring progress.
Number of subjects: 0
Study 37592359 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 37592403 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mL of 40% ethanol per kg body weight via a nasogastric tube
Number of subjects: 38
Study 37592403 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 38
Study 37592860 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) combined with language therapy
Number of subjects: 0
Study 37592860 — intervention group
Group type: COMPARATOR
Intervention: Language treatment alone (Control)
Number of subjects: 0
Study 37592858 — intervention group
Group type: EXPERIMENTAL
Intervention: γδ T cell-based immunotherapeutic strategies; specific dosage and duration not available
Number of subjects: 0
Study 37593110 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid comprehensive telerehabilitation (HCTR)
Number of subjects: 1578
Study 37593110 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation care
Number of subjects: 1578
Study 37593221 — intervention group
Group type: EXPERIMENTAL
Intervention: sintilimab plus bevacizumab (200 mg and 7.5 mg/kg respectively, intravenously every 3 weeks)
Number of subjects: 33
Study 37593221 — intervention group
Group type: EXPERIMENTAL
Intervention: sintilimab plus bevacizumab
Number of subjects: 33
Study 37593224 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult-onset T1D
Number of subjects: 218
Study 37593224 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 218
Study 37593224 — intervention group
Group type: COMPARATOR
Intervention: Type 2 Diabetes (T2D)
Number of subjects: 218
Study 37593227 — intervention group
Group type: EXPERIMENTAL
Intervention: AK112 combined with pemetrexed (500 mg/m2) in cohort 1 (previously untreated)
Number of subjects: 83
Study 37593227 — intervention group
Group type: EXPERIMENTAL
Intervention: AK112 combined with chemotherapy in cohort 2 (EGFR-functional mutation)
Number of subjects: 83
Study 37593227 — intervention group
Group type: EXPERIMENTAL
Intervention: AK112 combined with chemotherapy in cohort 3 (failed prior systemic treatments)
Number of subjects: 83
Study 37593752 — intervention group
Group type: EXPERIMENTAL
Intervention: feladilimab (anti-ICOS mAb)
Number of subjects: 0
Study 37593752 — intervention group
Group type: EXPERIMENTAL
Intervention: feladilimab (anti-ICOS mAb) + pembrolizumab (PD-1 inhibitor)
Number of subjects: 0
Study 37593833 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management program led by registered nurses (RNs)
Number of subjects: 330
Study 37593833 — intervention group
Group type: COMPARATOR
Intervention: Diabetes self-management program led by community health workers
Number of subjects: 330
Study 37593838 — intervention group
Group type: EXPERIMENTAL
Intervention: DWP16001 (2 mg)
Number of subjects: 24
Study 37593838 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine (37.5 mg)
Number of subjects: 24
Study 37593838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DWP16001 and phentermine
Number of subjects: 24
Study 37593838 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study 37593881 — intervention group
Group type: EXPERIMENTAL
Intervention: Vimseltinib 30 mg twice weekly for up to 24 weeks
Number of subjects: 0
Study 37593881 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive substance) for up to 24 weeks
Number of subjects: 0
Study 37594044 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 200 mg subcutaneous every 4 or 12 weeks through week 52
Number of subjects: 38
Study 37594044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 37594640 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus Letrozole
Number of subjects: 130
Study 37594646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripple mapping-guided isthmus ablation
Number of subjects: 200
Study 37594646 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 200
Study 37594667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer stress
Number of subjects: 76
Study 37594667 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 stress
Number of subjects: 76
Study 37594766 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37594769 — intervention group
Group type: COMPARATOR
Intervention: Algorithmic approach to ventilator withdrawal; details on dosage and duration not available.
Number of subjects: 0
Study 37594769 — intervention group
Group type: COMPARATOR
Intervention: Standard care for ventilator withdrawal; details on dosage and duration not available.
Number of subjects: 0
Study 37594793 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable devices and AI (smartwatches collecting physiological data)
Number of subjects: 40
Study 37594946 — intervention group
Group type: EXPERIMENTAL
Intervention: Play-based, parent-delivered intervention focusing on regaining pre-treatment mobility and midline crossing until 7 weeks post-treatment, individualized from 7 weeks to 6 months post-treatment.
Number of subjects: 0
Study 37594946 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 37595029 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app + booklet with patient-facing guidelines
Number of subjects: 74
Study 37595029 — intervention group
Group type: COMPARATOR
Intervention: Booklet with guidelines alone
Number of subjects: 74
Study 37595058 — intervention group
Group type: EXPERIMENTAL
Intervention: GATA2 enhancer mutation
Number of subjects: 0
Study 37595058 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR/Cas9-modified HL-60 cells
Number of subjects: 0
Study 37595058 — intervention group
Group type: EXPERIMENTAL
Intervention: Luciferase assays with the enhancer mutation
Number of subjects: 0
Study 37595103 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil (single-dose)
Number of subjects: 94
Study 37595103 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir (twice-daily for 5 days)
Number of subjects: 94
Study 37595843 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 407
Study 37595843 — intervention group
Group type: COMPARATOR
Intervention: No Pregnancy (Control)
Number of subjects: 407
Study 37595984 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus two additional PoCUS performed at 2-hour intervals from the initial PoCUS (serial ultrasound group)
Number of subjects: 206
Study 37595984 — intervention group
Group type: COMPARATOR
Intervention: Usual care including a single cardiopulmonary PoCUS within 1 hour of arrival (control group)
Number of subjects: 206
Study 37596006 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS training and mobile application for scoring
Number of subjects: 447
Study 37596006 — intervention group
Group type: COMPARATOR
Intervention: Standard stroke protocol (control group)
Number of subjects: 447
Study 37596158 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai-chi exercise for 12 months
Number of subjects: 15
Study 37596191 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 172
Study 37596281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal adenoviral vectored SARS-CoV-2 vaccine (BBV154)
Number of subjects: 0
Study 37596281 — intervention group
Group type: COMPARATOR
Intervention: Licensed intramuscular vaccine, Covaxin
Number of subjects: 0
Study 37596280 — intervention group
Group type: EXPERIMENTAL
Intervention: CoVac-1 (one subcutaneous dose)
Number of subjects: 54
Study 37596323 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-channel NMES
Number of subjects: 17
Study 37596323 — intervention group
Group type: COMPARATOR
Intervention: 2-channel NMES
Number of subjects: 17
Study 37596391 — intervention group
Group type: EXPERIMENTAL
Intervention: RET-He
Number of subjects: 0
Study 37596391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin
Number of subjects: 0
Study 37596428 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) with Probenecid
Number of subjects: 0
Study 37596428 — intervention group
Group type: COMPARATOR
Intervention: N-Acetylcysteine (NAC)
Number of subjects: 0
Study 37596428 — intervention group
Group type: COMPARATOR
Intervention: Probenecid
Number of subjects: 0
Study 37596449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 61
Study 37596449 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy alone
Number of subjects: 61
Study 37596449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with complete cytoreduction (CC-0)
Number of subjects: 61
Study 37596461 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment (not specified dosage or duration)
Number of subjects: 0
Study 37596461 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (not specified dosage or duration)
Number of subjects: 0
Study 37596524 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic resonance-guided focused ultrasound (MRgFUS) pallidothalamic tractotomy
Number of subjects: 0
Study 37596524 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical data collection
Number of subjects: 0
Study 37596541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention (neuropsychological psychoeducation)
Number of subjects: 130
Study 37596541 — intervention group
Group type: COMPARATOR
Intervention: Affective intervention (emotion management with cognitive-behavioural counselling)
Number of subjects: 130
Study 37596549 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Elder Care (MBEC) program for 8 weeks
Number of subjects: 77
Study 37596549 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 37596551 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional tests including Lower Quarter Y-Balance Test (YBT-LQ), single-legged hop tests, isokinetic strength tests, and self-reported function measured with Banff Patellofemoral Instability Instrument 2.0 (BPII) and Norwich Patellar Instability score (NPI).
Number of subjects: 78
Study 37596551 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional assessment at 6 months post-surgery.
Number of subjects: 78
Study 37596551 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of surgery (MPFL-R only vs combined surgery).
Number of subjects: 78
Study 37596568 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance during the first seven days of residential stay
Number of subjects: 44
Study 37596613 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted partial nephrectomy at low insufflation pressure (7 mmHg)
Number of subjects: 0
Study 37596613 — intervention group
Group type: COMPARATOR
Intervention: Robot-assisted partial nephrectomy at standard insufflation pressure (12 mmHg)
Number of subjects: 0
Study 37596658 — intervention group
Group type: EXPERIMENTAL
Intervention: clip + iodine seed
Number of subjects: 189
Study 37596658 — intervention group
Group type: EXPERIMENTAL
Intervention: magnetic seed
Number of subjects: 189
Study 37596658 — intervention group
Group type: EXPERIMENTAL
Intervention: carbon suspension
Number of subjects: 189
Study 37596658 — intervention group
Group type: COMPARATOR
Intervention: clip + iodine seed, magnetic seed, carbon suspension
Number of subjects: 189
Study 37596658 — intervention group
Group type: EXPERIMENTAL
Intervention: targeted lymph nodes (TLN)
Number of subjects: 189
Study 37596887 — intervention group
Group type: EXPERIMENTAL
Intervention: Fugl-Meyer assessment (FM-LE)
Number of subjects: 48
Study 37596887 — intervention group
Group type: EXPERIMENTAL
Intervention: Motricity Index total score (MI-LE)
Number of subjects: 48
Study 37596887 — intervention group
Group type: EXPERIMENTAL
Intervention: Motricity Index ankle item (MI-ankle)
Number of subjects: 48
Study 37596887 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-of-pressure area (COP) during quiet 2-legged stance
Number of subjects: 48
Study 37597095 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Hyperparathyroidism (PHPT)
Number of subjects: 41
Study 37597153 — intervention group
Group type: EXPERIMENTAL
Intervention: Idecabtagene vicleucel (ide-cel) treatment
Number of subjects: 128
Study 37597159 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (subcutaneous 100 mg at weeks 0, 4, and every 8 weeks)
Number of subjects: 114
Study 37597161 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulations (RAS)
Number of subjects: 10
Study 37597161 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Vibrotactile Stimulations (RVS)
Number of subjects: 10
Study 37597161 — intervention group
Group type: COMPARATOR
Intervention: Control Condition (CC)
Number of subjects: 10
Study 37597246 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib (45 mg twice daily) plus Panitumumab (6 mg/kg every 2 weeks)
Number of subjects: 53
Study 37597326 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) treatment
Number of subjects: 257
Study 37597507 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise on a bicycle ergometer
Number of subjects: 91
Study 37597507 — intervention group
Group type: COMPARATOR
Intervention: Flexibility, strengthening, and balance training
Number of subjects: 91
Study 37597522 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based albuminuria screening by urine collection device (UCD)
Number of subjects: 15074
Study 37597522 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based albuminuria screening by smartphone application method
Number of subjects: 15074
Study 37597523 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 1.5 mg plus piroxicam 40 mg
Number of subjects: 860
Study 37597523 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel 1.5 mg plus placebo
Number of subjects: 860
Study 37597724 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP (turoctocog alfa pegol; Esperoct)
Number of subjects: 81
Study 37597750 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Number of subjects: 304
Study 37597750 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab
Number of subjects: 304
Study 37597856 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block
Number of subjects: 75
Study 37597856 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 75
Study 37597868 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 261
Study 37597865 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged fasting (PF) followed by time-restricted eating (TRE) for 12 months
Number of subjects: 180
Study 37597865 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 180
Study 37597873 — intervention group
Group type: EXPERIMENTAL
Intervention: OnTrack intervention (12-week package including movement targets, activity tracking, motivational messaging, self-management coaching)
Number of subjects: 11
Study 37597873 — intervention group
Group type: EXPERIMENTAL
Intervention: OnTrack intervention (activity tracking)
Number of subjects: 11
Study 37597873 — intervention group
Group type: EXPERIMENTAL
Intervention: OnTrack intervention (motivational messaging)
Number of subjects: 11
Study 37597873 — intervention group
Group type: EXPERIMENTAL
Intervention: OnTrack intervention (self-management coaching)
Number of subjects: 11
Study 37597873 — intervention group
Group type: EXPERIMENTAL
Intervention: OnTrack intervention (remote monitoring)
Number of subjects: 11
Study 37597873 — intervention group
Group type: EXPERIMENTAL
Intervention: OnTrack intervention (coaching role)
Number of subjects: 11
Study 37597877 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted counselling (CAC)
Number of subjects: 120
Study 37597877 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 120
Study 37597969 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg BI 1015550
Number of subjects: 0
Study 37597969 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mg BI 1015550
Number of subjects: 0
Study 37597969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37597969 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (9 mg, 18 mg, placebo)
Number of subjects: 0
Study 37598000 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaphorins and their receptors (plexins and neuropilins) as regulatory signals in pancreatic cancer treatment
Number of subjects: 0
Study 37598032 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted simple enucleation (RASE)
Number of subjects: 380
Study 37598032 — intervention group
Group type: COMPARATOR
Intervention: Standard robot-assisted partial nephrectomy (sRAPN)
Number of subjects: 380
Study 37598161 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-social hassles intensity for the worsened group
Number of subjects: 128
Study 37598161 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-social hassles intensity for the improved group
Number of subjects: 128
Study 37598161 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of non-social uplifts for the worsened group
Number of subjects: 128
Study 37598161 — intervention group
Group type: COMPARATOR
Intervention: Work status for non-improved groups
Number of subjects: 128
Study 37598176 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG-controlled serious games with MYO Armband® and conventional rehabilitation
Number of subjects: 0
Study 37598176 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation only
Number of subjects: 0
Study 37598194 — intervention group
Group type: EXPERIMENTAL
Intervention: P11-4
Number of subjects: 66
Study 37598194 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosilver Fluoride (NSF)
Number of subjects: 66
Study 37598194 — intervention group
Group type: COMPARATOR
Intervention: Sodium Fluoride (NaF)
Number of subjects: 66